Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 13/20 | 0.58 |
| ▸ | ESRRB | O95718 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ESRRG | P62508 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
| ▸ | VHL | P40337 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648917 | 1.00 | ESRRA (0.58) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL4403335 | 0.90 | ESRRA (0.45) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL4401164 | 0.89 | NPSR1 (0.51) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648904 | 0.88 | ESRRA (0.58) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL651323 | 0.88 | ESRRA (0.58) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL649112 | 0.87 | ESRRA (0.58) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL649113 | 0.87 | ESRRA (0.58) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648616 | 0.86 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL648615 | 0.86 | ESRRA (0.62) | ESRRAESRRBESR1ESRRGESR2 | |
| SCHEMBL26508835 | 0.85 | ESRRA (0.68) | ESRRAESRRBESR1ESRRGESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015157158-A1 | SYSTEMS AND METHODS FOR ACCELERATING PRODUCTION OF VISCOUS HYDROCARBONS IN A SUBTERRANEAN RESERVOIR WITH CHEMICAL AGENTS THAT LOWER WATER-OIL INTERFACIAL TENSION | REES ANDREW C (US) | 2015-10-15 | — | — | WO | claimed |
| WO-2015157156-A1 | SYSTEMS AND METHODS FOR ACCELERATING PRODUCTION OF VISCOUS HYDROCARBONS IN A SUBTERRANEAN RESERVOIR WITH EMULSIONS COMPRISING CHEMICAL AGENTS | FU XUEBING (US) | 2015-10-15 | — | — | WO | claimed |
| US-20140302087-A1 | MANUFACTURE OF VACCINES THAT CONTAIN BOTH HEPATITIS B VIRUS SURFACE ANTIGEN AND SURFACTANT | NOVARTIS VACCINES AND DIAGNOSTICS, SRL (IT) | 2014-10-09 | — | — | US | claimed |
| US-8119669-B2 | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-21 | — | — | US | claimed |
| EP-2132188-B1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLEDINEDIONE AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-14 | — | — | EP | claimed |
| US-20100167340-A1 | METHOD TO PRODUCE A RECEPTOR CHIP USING BIOTINYLATED PROTEIN | NATIONAL FOOD RESEARCH INSTITUTE (JP) | 2010-07-01 | — | — | US | claimed |
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | claimed |
| WO-2006096727-A2 | METHODS FOR DETECTING INTEGRATED DNA | CELLAY LLC (US) | 2006-09-14 | — | — | WO | claimed |
| US-6852833-B1 | Artificial chaperon kit | DIRECTOR OF NATIONAL FOOD RESEARCH INSTITUTE, MINISTRY OF AGRICULTURE, FORESTRY AND FISHERIES (JP) | 2005-02-08 | — | — | US | claimed |
| US-20040209294-A1 | Method to produce a receptor chip using biotinylated protein | NATIONAL FOOD RESEARCH INSTITUTE (JP) | 2004-10-21 | — | — | US | claimed |
| WO-1999061473-A1 | METHOD FOR PURIFICATION OF BORRELIA LIPOPROTEIN OSPA | SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) | 1999-12-02 | — | — | WO | claimed |
| EP-0750678-B1 | NOVEL METHOD FOR THE CONDITIONING OF LIQUID SAMPLES | FOSS ELECTRIC AS (DK) | 1999-09-08 | — | — | EP | claimed |
| WO-1998045311-A1 | RNA ISOLATION REAGENT AND METHODS | LIFE TECHNOLOGIES, INC. (US) | 1998-10-15 | — | — | WO | claimed |
| US-5798221-A | Method for the conditioning of liquid samples | FOSS ELECTRIC A/S (DK) | 1998-08-25 | — | — | US | claimed |
| US-5690942-A | SQUALENE, LECITHIN, SURFACTANT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-11-25 | — | — | US | claimed |
| US-5577999-A | Orthopaedic supporter kit | ALCARE, CO. LTD. (JP) | 1996-11-26 | — | — | US | claimed |
| EP-0270503-B1 | UTILIZATION OF BROMURE D'OTILONIUM (DCI) FOR TOPIC APPLICATION IN THE GASTROINTESTINAL TRACT AND RELATIVE PHARMACEUTICAL FORMULATION APPROPRIATE FOR SUCH USE | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1993-09-15 | — | — | EP | claimed |
| EP-0219295-A2 | Process for producing human growth hormone | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JCR PHARMACEUTICALS CO., LTD (JP) | 1987-04-22 | — | — | EP | claimed |
| US-4565547-A | FATTY ACID, AMINE OR AMMONIA, ANIONIC SURFACTANT | TOYOTO JIDOSHA KABUSHIKI KAISHA (JP) | 1986-01-21 | — | — | US | claimed |
| US-4543253-A | ANTITUMOR | YAMAMURA YUICHI (JP) | 1985-09-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286265-A1 | SUBSTITUTED PHENOXY N-ALKYLATED THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, ESRRG | ESRRA 2/4885ESRRB 4/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.